印度政府规定,由于取消关税和降低GST,3种抗癌药物的价格降低。 Indian govt mandates price reduction for 3 anti-cancer drugs due to customs duty elimination and GST decrease.

印度政府已授权在取消关税和将货物和服务税从12%降至5%之后,降低三种抗癌症药物——Trastuzumab、Osimertinib和Durvalumab的价格。 The Indian government has mandated a price reduction for three anti-cancer drugs—Trastuzumab, Osimertinib, and Durvalumab—following the elimination of customs duties and a decrease in Goods and Services Tax (GST) from 12% to 5%. 国家药品定价局(NPPA)指示制造商调整最高零售价格,并向有关当局提供最新价格清单,以提高癌症病人的药物价格。 The National Pharmaceutical Pricing Authority (NPPA) instructed manufacturers to adjust Maximum Retail Prices (MRP) and provide updated price lists to relevant authorities, aiming to enhance drug affordability for cancer patients.